文献速递皮肤肿瘤

放疗与局部咪喹莫特治疗恶性雀斑样痣的成本比较

A cost comparison of radiotherapy and topical imiquimod for lentigo maligna treatment: Considerations for clinical decision-making.
PubMed 文献 · J Am Acad Dermatol · 2025-12-18

基于RADICAL随机试验(118/126例完成治疗,咪喹莫特60例、放疗58例)的成本分析显示,放疗的医疗系统成本为每例2673.43美元,远高于咪喹莫特的72.50美元;从社会视角看,放疗总成本4379.22美元,咪喹莫特为697.94美元。咪喹莫特是更具成本效益的治疗选择,应优先考虑以患者为中心的共享决策。

要点

  • 放疗每例医疗系统成本2673.43美元,咪喹莫特仅72.50美元。
  • 放疗平均治疗访次27.39次,咪喹莫特6.25次。
  • 社会视角总成本放疗4379.22美元,咪喹莫特697.94美元。

核心结论

  • 与放疗相比,咪喹莫特是治疗恶性雀斑样痣更具成本效益的选择。
  • 应优先考虑以患者为中心的共享决策。

研究设计与样本

  • 基于RADICAL试验的成本分析,该试验为多机构1:1随机3期研究,在澳大利亚、新西兰和巴西开展。
  • 118/126例随机患者完成治疗,其中咪喹莫特60例、放疗58例。
  • 从医疗系统和社会视角估算直接医疗成本和间接成本(生产力损失和旅行时间)。

主要发现

  • 每例医疗系统成本放疗为2673.43美元,咪喹莫特为72.50美元。
  • 放疗所需治疗访次多于咪喹莫特(平均27.39次 vs 6.25次)。
  • 放疗导致更大的生产力损失和旅行时间成本。
  • 社会视角总成本放疗为4379.22美元,咪喹莫特为697.94美元。

关键数值与推荐

  • 近期随机试验显示放疗与局部咪喹莫特在治疗失败方面无差异(因疫情中断而把握度不足)。

临床怎么用

  • 在临床决策中可将咪喹莫特作为更具成本效益的替代方案。
  • 结合患者偏好和成本因素进行共享决策。

局限性

  • 分析仅依赖澳大利亚医疗保健成本数据。
  • 未纳入对退休患者的货币影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lentigo maligna (LM) is an in situ melanoma occurring on sun-damaged skin. Radiotherapy or topical imiquimod are potential alternatives to surgery; a recent randomized trial showed no difference in treatment failure between those approaches (underpowered because of pandemic disruption). OBJECTIVE: To conduct an economic evaluation comparing radiotherapy versus topical imiquimod for treating LM. METHODS: Based on no difference in clinical outcomes, a cost analysis was performed alongside the RADICAL trial, a multi-institutional randomized (1:1) phase 3 study (118/126 patients randomized completed treatment; 60 imiquimod and 58 radiotherapy) conducted in Australia, New Zealand, and Brazil. Direct medical costs and indirect costs (productivity loss and travel time) were estimated from health care system and societal perspectives. RESULTS: Health care system costs per patient were substantially higher for radiotherapy (US$2673.43) than imiquimod (US$72.50). Radiotherapy required more treatment visits than imiquimod (average, 27.39 vs 6.25) and resulted in greater productivity losses and travel time costs. Thus, from a societal perspective, radiotherapy costs totaled US$4379.22 versus US$697.94 for imiquimod. LIMITATIONS: Analysis relied solely on Australian health care cost data and did not capture monetary impacts on retired patients. CONCLUSION: Imiquimod represents a substantially more cost-effective treatment option for managing LM compared with radiotherapy. Patient-centered shared decision-making should be prioritized.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Guitera P, Lo SN, Stretch J, et al. A cost comparison of radiotherapy and topical imiquimod for lentigo maligna treatment: Considerations for clinical decision-making. J Am Acad Dermatol. 2025. PMID: 41421462. doi:10.1016/j.jaad.2025.12.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。